Paper22909192
Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.
Klyuchnikov E and 10 others. Br J Haematol, 2012. Cited by 47 papers, by iCite.
Cite this record
ConductScience Library. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Papers, record 22909192. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22909192
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hematopoietic Stem Cell Transplantation | Major topic |
| Living Donors | Major topic |
| Lymphocyte Transfusion | Major topic |
| Primary Myelofibrosis | Major topic |
| Acute Disease | |
| Adult | |
| Aged | |
| Disease-Free Survival | |
| Female | |
| Follow-Up Studies | |
| Graft vs Host Disease | |
| Humans | |
| Male | |
| Middle Aged | |
| Salvage Therapy | |
| Survival Rate | |
| Transplantation, Homologous |
Source PubMed
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42776827 | Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: Evolving Indications, Conditioning Strategies, and Outcomes. | Hematol Rep | 2026 | https://conductscience.org/library/papers/42776827 | PubMed |
| 40119918 | Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes. | Ann Hematol | 2025 | https://conductscience.org/library/papers/40119918 | PubMed |
| 40079242 | Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review. | Am J Hematol | 2025 | https://conductscience.org/library/papers/40079242 | PubMed |
| 38321269 | Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/38321269 | PubMed |
| 37404772 | Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation. | Hemasphere | 2023 | https://conductscience.org/library/papers/37404772 | PubMed |
| 37365186 | Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation. | Blood Cancer J | 2023 | https://conductscience.org/library/papers/37365186 | PubMed |
| 36959692 | Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center | Balkan Med J | 2023 | https://conductscience.org/library/papers/36959692 | PubMed |
| 36940410 | Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. | Blood | 2023 | https://conductscience.org/library/papers/36940410 | PubMed |
| 35419771 | Improving allogeneic stem cell transplantation in myelofibrosis. | Int J Hematol | 2022 | https://conductscience.org/library/papers/35419771 | PubMed |
| 35051996 | Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis. | Blood Adv | 2022 | https://conductscience.org/library/papers/35051996 | PubMed |
| 34040148 | Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. | Leukemia | 2021 | https://conductscience.org/library/papers/34040148 | PubMed |
| 34017327 | Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021. | Front Immunol | 2021 | https://conductscience.org/library/papers/34017327 | PubMed |
| 33824436 | Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. | Bone Marrow Transplant | 2021 | https://conductscience.org/library/papers/33824436 | PubMed |
| 33718228 | Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. | Front Oncol | 2021 | https://conductscience.org/library/papers/33718228 | PubMed |
| 33114179 | Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33114179 | PubMed |
| 32806517 | Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32806517 | PubMed |
| 32110286 | Allogeneic hematopoietic stem-cell transplantation for myelofibrosis. | Ther Adv Hematol | 2020 | https://conductscience.org/library/papers/32110286 | PubMed |
| 31296578 | Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. | Haematologica | 2021 | https://conductscience.org/library/papers/31296578 | PubMed |
| 28714945 | Impact of molecular residual disease post allografting in myelofibrosis patients. | Bone Marrow Transplant | 2017 | https://conductscience.org/library/papers/28714945 | PubMed |
| 28499938 | Allogeneic Stem Cell Transplantation in Myelofibrosis. | Biol Blood Marrow Transplant | 2017 | https://conductscience.org/library/papers/28499938 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22909192
GET https://conductscience.org/api/papers/v1/22909192/cited_by?page=2